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Abstract: This paper looks at the way in which industrial pharmacists rank the fundamental
competences for pharmacy practice. European industrial pharmacists (n = 135) ranked 68 competences
for practice, arranged into 13 clusters of two types (personal and patient care). Results show that,
compared to community pharmacists (n = 258), industrial pharmacists rank competences centering
on research, development and production of drugs higher, and those centering on patient care lower.
Competences centering on values, communication skills, etc. were ranked similarly by the two groups
of pharmacists. These results are discussed in the light of the existence or not of an “industrial
pharmacy” specialization.
Keywords: education; specialization; practice
1. Introduction
Graduates with a pharmacy degree are employed in a variety of positions, the most important
(in terms of numbers) being community, hospital and industrial pharmacy. The discussion on
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whether these three domains require specific skills with a specific education has long been contentious.
Industrial pharmacy as a university discipline is recognized by some European pharmacy departments.
The PHARMINE study (Pharmacy Education in Europe) reported that pharmacy departments in 10/31
European countries give elective pre-graduate courses in industrial pharmacy, and 11/31 departments
give post-graduate industrial pharmacy courses [1]. Most of the graduates from such courses go on to
to work in an industrial setting. The PHARMINE study reported that a substantial number (37,308) of
European pharmacists (6% of the industrial workforce) work in the pharmaceutical industry [2]; this is
similar to the worldwide figure of 10% given by the International Pharmaceutical Federation [3].
In some European countries the status of the industrial pharmacist is officially recognized. In
France, the profession of “industrial pharmacist” is defined by national law and the statutes of the
pharmacy professional body [4]. On the global European level, this is not the case. In the European
Union (EU), the 1985 EU directive on the profession of pharmacy [5], and the 2013 update [6], do not
recognize any specialization in pharmacy (although these are recognized in medicine).
There is a second EU directive that is relevant in this case, however, and that is the EU directive
on qualified persons working in the pharmaceutical industry [7]. In some EU member states, such
as Germany [8], only those with a pharmacy degree meet the requirements set down in the qualified
persons directive.
It appears, therefore, that the argument is equivocal for the existence of a specialized pharmacy
job description of “industrial pharmacist” (i.e., a pharmacist working in industry) that is different
from that of other specialties such as community pharmacy. This paper looks at one aspect of
this discussion: whether industrial pharmacists rank competences for practice differently than do
community pharmacists. It is possible that pharmacists working within such specialties view the
pharmacy profession differently. Within this context we investigated, therefore, whether the ranking
by industrial pharmacists of competences for practice is different from that of community pharmacists.
In the PHAR-QA (“Quality Assurance in European PHARmacy Education and Training”) project [9],
we asked community and industrial pharmacists to rank competences for pharmacy practice. This
paper describes the similarities and differences between the ways in which European industrial and
community pharmacists respectively rank competences for pharmacy practice.
2. Experimental Section
Ranking data on competences for practice were obtained using the PHAR-QA surveymonkey [10]
questionnaire that was available online from 14 February 2014 to 1 November 2014, i.e., 8.5 months [11].
Respondents came from 36/49 countries of the European Higher Education Area [12].
The first six questions were on the profile of the respondent (duration of practice, country of
residence, current occupation (industrial, community . . . pharmacist)). There was also a question on
the job title. This allowed a subdivision of industrial pharmacists according to their experience/activity:
regulatory affairs, research and development, etc. A similar subdivision of the activities of community
pharmacists was not possible, as all respondents in this group were involved in some form of
dispensation to patients.
Questions 7 through 19 asked about 13 clusters of 68 competences (see Appendix A). Questions
in clusters 7 to 11 were concerned with personal competences, and in clusters 12 to 19 with patient
care competences.
Respondents were asked to rank the proposals for competences on a 4-point Likert scale:
(1) Not important = Can be ignored;
(2) Quite important =Valuable but not obligatory;
(3) Very important = Obligatory, with exceptions depending upon field of pharmacy practice;
(4) Essential = Obligatory.
There was also a “cannot rank” possibility as well as that of leaving the answer blank.
Results are presented in the form of “scores” calculated as follows:
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Ranking score = (frequency rank 3 + frequency rank 4) as % of total frequency, which represents
the percentage of respondents that considered a given competence as “obligatory”.
This calculation is based on a similar calculation made by the MEDINE consortium that studied
the ranking of competences for medical practice [13]. Such scores are used for descriptive purposes
only, and no conclusions on statistical differences amongst groups are based on scores.
Leik ordinal consensus [14] was calculated as an indication of the dispersion of the data using an
Excel spreadsheet. The original Leik paper cited previously gives an explicit mathematical example of
the calculation of ordinal consensus. Responses for consensus were arbitrarily classified as: < 0.2 poor,
0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8 substantial, > 0.81 good, according to the scale used in MEDINE study.
The statistical significance of differences between rankings of competences or between rankings by
different categories of respondents was tested by the chi-square test (confidence level 95%). Statistical
tests were performed using GraphPad software [15].
Results are presented at 2 levels: that of the 13 clusters and that of the 68 competences.
Respondents could also add their comments on the different clusters. An attempt was made to
analyze comments using the NVivo10 program [16] for the semi-quantitative analysis of unstructured
data. It was found that the numbers involved were too small to draw significant conclusions.
3. Results and Discussion
The distribution by duration of practice of the groups is given in Table 1.
Table 1. Distribution of duration of practice (years) in industrial and community pharmacist responders.
n: number in each category.
Respondents < 5 6–10 11–20 21–40 Blank Total
Industrial pharmacists (n) 26 31 28 23 27 135
Community pharmacists (n) 50 51 41 56 60 258
Most respondents had less than 20 years of experience, thus in both cases a relatively “young”
population was involved. This may be due to the higher motivation of a younger population to reply
to a questionnaire.
Respondents came from 36 European countries. Nineteen countries provided 5 or more
respondents to one or both groups; they were: Belgium, Croatia, Czech Republic, Estonia, Finland,
Germany, Greece, Hungary, Ireland, Italy, Macedonia, Montenegro, Norway, Romania, Slovenia, Spain,
Switzerland, The Netherlands, and the United Kingdom.
The numbers of industrial pharmacy respondents arranged according to experience/activity are
given in Table 2.
Table 2. Numbers of industrial pharmacy respondents subdivided according to experience/activity.
Experience/Activity Number
Management 24
Regulatory affairs 23
Research and development 18
Quality assurance/compliance 16
Pharmaceutical technology 10
Clinical/medical affairs 8
Pharmacovigilance 5
Qualified person 5
Marketing and sales 5
Research student/Ph.D. 1
“Industrial pharmacist” or “pharmacist” 8
Blank 12
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Table 2 shows that, while some respondents work in a typically “pharmaceutical” environment
(such as regulatory affairs and pharmaceutical technology), many others work in more “generic”
environments (such as management and quality assurance). If we consider that industrial surroundings
correspond to 4 groups/stages, namely (1) research and development; (2) production; (3) analyses
and quality assurance; and (4) marketing and sales, it appears that not all pharmacists employed
in marketing and sales feel that they are industrial pharmacists. Indeed, marketing and sales
representatives of “big pharma” are sometimes very far from classical industrial surroundings, even
though they are employed in industry.
Table 3 shows the overall distribution of rankings by industrial and community pharmacists.
Table 3. Overall distribution (over 13 clusters of 68 competences) of rankings by industrial and
community pharmacists.
Ranking Industrial Pharmacists Community Pharmacists
Number of respondents 138 258
Theoretical number of
replies 9384 (= 138 ˆ 68) 17,544 (= 258 ˆ 68)
Rank Number % Number %
4 2510 26.8 6643 37.9
3 3502 37.3 6002 34.2
2 1876 20.0 3076 17.5
1 432 4.6 608 3.5
Cannot rank + blanks 1064 11.3 1215 6.9
Score (%) =((2510 + 3502)/8320) ˆ 100) = 72.3 = ((6643 + 6002)/16,329) ˆ 100 = 77.4
Leik ordinal consensus 0.58 0.55
Notes: Chi-square test on distribution of ranks for industrial versus community pharmacists: p < 0.05 (degrees
of freedom = 3, ((4 ranks ´1) ˆ (2 groups ´1)).
All but 7–11% of respondents were able to rank all competences. This suggests that the majority
in both groups of respondents believed that they were sufficiently informed to reply to almost all the
questions asked.
As judged from the Leik ordinal consensus values, dispersion was low. This suggests that
both groups were relatively homogeneous and that subgroups with responses significantly different
from the overall group do not exist. Similar values for ordinal consensus have been reported by the
MEDINE consortium.
Overall ranking by industrial pharmacists was significantly lower (72%) than that by community
pharmacists (77%). This raises the question of whether industrial pharmacists globally believed that
the competence framework was less applicable; however, the global score was high with almost 3/4 of
industrial pharmacists considering the competences “obligatory”. The global lower score of industrial
pharmacists was weighted by the low scores they gave to patient care competences (see later).
Figures 1 and 2 show the results for analysis by clusters. In Figure 1, the values for Leik ordinal
consensus are shown.
Leik ordinal consensus was higher for industrial pharmacists in 10/13 clusters including cluster
11 that dealt with competences for industrial pharmacy.
Scores for personal competences (clusters 7 to 11) were similar in industrial and community
pharmacists, except for cluster 11, dealing with industrial pharmacy, for which industrial pharmacists
scored higher. Scores for clusters dealing with patient care competences (clusters 12 to 19) were lower
for industrial pharmacists.
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line) pharmacists. Dashed lines separate the different clusters of competences.
Overall, the ordinal consensus values were higher for industrial than for co munity pharmacists.
This was especially true for competences 6 (research), 18 (development, production of medicines),
28 (analytical chemistry), 38 (design, synthesis, etc. of active substances), 40 (EU directive on
qualified persons), and 41 (drug registration, licensing and marketing). For all these competences,
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the consensus for industrial pharmacists was higher than community pharmacists (Figure 4 and
Appendix A). For competences 31 (microbiology) and 44 (diagnostic tests) the ordinal consensus for
community pharmacists was higher than that for industrial pharmacists, as were the scores (Figure 4
and Appendix A).
Scores for the 68 competences are given in Figure 4 and the Appendix A.
This graph shows that competences on the right-hand side concerned with personal values, subject
matters and industrial pharmacy were often ranked higher by industrial pharmacists. Competences on
the left-hand side concerned with patient care were often ranked higher by community pharmacists.
A proviso must be added here; through a comparison between Figure 4 with Figure 3, it is obvious
that, for competences scoring low (e.g., 24 and 25), consensus was low. Thus, the low ranking was far
from unanimous.
Going into more detail, Table 4 shows the competences for which industrial pharmacist ranked
higher (upper) and for which community pharmacists ranked higher (lower).
Table 4. Competences ranked higher by industrial pharmacist (upper) and by community pharmacists
(lower). (a) Industrial > community; (b) Community > industrial.
(a)
n Competence
4 Capacity to evaluate scientific data in line with current scientific and technological knowledge
6 Ability to design and conduct research using appropriate methodology
18 Ability to design and manage the development processes in the production of medicines
25 Physics
28 Analytical chemistry
34 Pharmaceutical technology including analyses of medicinal products
38 Current knowledge of design, synthesis, isolation, characterization and biological evaluation ofactive substances
39 Current knowledge of good manufacturing practice (GMP) and of good laboratory practice (GLP)
40 Current knowledge of European directives on qualified persons (QPs)
41 Current knowledge of drug registration, licensing and marketing
(b)
n Competence
24 Plant and animal biology
30 Anatomy and physiology; medical terminology
33 Pharmacotherapy and pharmaco-epidemiology
36 Pharmacognosy
43 Ability to perform and interpret medical laboratory tests
44 Ability to perform appropriate diagnostic or physiological tests to inform clinical decision making(e.g., measurement of blood pressure)
45 Ability to recognise when referral to another member of the healthcare team is needed because apotential clinical problem is identified (pharmaceutical, medical, psychological or social)
46 Retrieval and interpretation of relevant information on the patient’s clinical background
47 Retrieval and interpretation of an accurate and comprehensive drug history if and when required
48 Identification of non-adherence and implementation of appropriate patient intervention
49 Ability to advise to physicians and, in some cases, prescribe medication
50 Identification, understanding and prioritization of drug-drug interactions at a molecular level(e.g., use of codeine with paracetamol)
51
Identification, understanding, and prioritization of drug-patient interactions, including those that
preclude or require the use of a specific drug (e.g., trastuzumab for treatment of breast cancer in women
with HER2 overexpression)
52 Identification, understanding, and prioritization of drug-disease interactions (e.g., NSAIDs inheart failure)
55 Critical evaluation of the prescription to ensure that it is clinically appropriate and legal
56 Familiarity with the supply chain of medicines and the ability to ensure timely flow of drug products tothe patient
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Table 4. Cont.
n Competence
58 Promotion of public health in collaboration with other actors in the healthcare system
59 Provision of appropriate lifestyle advice on smoking, obesity, etc.
60 Provision of appropriate advice on resistance to antibiotics and similar public health issues
61 Ability to use effective consultations to identify the patient’s need for information
62 Provision of accurate and appropriate information on prescription medicines
63 Provision of informed support for patients in selection and use of non-prescription medicines for minorailments (e.g., cough remedies)
64 Identification and prioritization of problems in the management of medicines in a timely manner andwith sufficient efficacy to ensure patient safety
66 Undertaking of a critical evaluation of prescribed medicines to confirm that current clinical guidelinesare appropriately applied
67 Assessment of outcomes on the monitoring of patient care and follow-up interventions
68 Evaluation of cost effectiveness of treatment
The competences ranked higher by industrial pharmacists fall into three groups with, firstly,
competences 4, 6 and 18 on evaluation of scientific data, research, and production of medicines.
Scores for community pharmacists on 2 of these competences (6, 18) were less than 50%. The second
group was concerned with the subject matters physics (25) 33%, analytical chemistry (28) 67%, and
pharmaceutical technology (34) 84%. Subject matters were included because they figure in the EU
directive on the sectoral profession of pharmacy. The authors recognize that they are not competences
but part of the foundation of competences. Having said that, it should be noted that community
pharmacists ranked these elements very low, with a score of 22% for physics and 42% for analytical
chemistry. Thus, the general message that all the subject matters cited in the EU directive are essential
for science-based pharmacy practice is not understood, as concerns subjects such as physics.
In the lower part of Table 4, the competences that are ranked higher by community pharmacists
are shown. Four of these concern subject areas (24, 30, 33, and 36), but the majority concern patient care
competences. For the latter community pharmacists scored significantly higher than industrial pharmacists
for all but five competences. This is not to say that industrial pharmacists scored low for patient care
competences, as almost all of their scores were between 60% and 80%. Thus, they do recognize the need
for information relating to the pharmacist as a medicine specialist (see also comments below).
Overall, the observations in the previous paragraphs suggest that the two groups are often ranking
in the context of their own specific activity and, following on from this, that certain competences
are needed for certain specializations. Continuing this argument further, certain competences could
thus be part of an “industrial pharmacy-oriented” degree course, and others part of a “community
pharmacy-oriented” degree course (taking for example, those in Table 4). An alternative argument
is that this is in favor of “amplifying” different clusters in different specializations within a single
curriculum, rather than “separating” competences into different curricula for the two activities.
Comments were made by 15/138 (11%) of industrial pharmacist and 23/258 (9%) of community
pharmacist respondents. Our initial objective was to evaluate whether comments were in line with
scoring, but the low numbers of comments received did not permit a satisfactory analysis using
semi-quantitative analysis of unstructured data (results not shown). Comments are reported here,
therefore, in a “raw data” form.
Comments are grouped into areas in Table 5.
There were several comments on the English phraseology and the construction of the questions,
and these have been taken into consideration in the production of the revised version of the
questionnaire. Others pointed to the esoteric nature of certain competences and the recognition
of specialization, be it industrial or community. Of interest also is the fact that industrial pharmacists
recognized the necessity of all competences, including patient care competences, and the nature of the
pharmacist as a “medicines specialist”.
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Table 5. Comments by industrial and community pharmacists.
Area
Typical Examples of Comments Made.
Industrial Pharmacist. Community Pharmacist.
Understanding of the
question
- I do not understand the question.
- I have not spoken English for a
long time.
- One point only to each question.
- Important to interpret but not
necessarily done.
- The question is very convoluted.
- The question is rather unclear.
Production of medicines. We buy rather than produce them.
Information sources.
- I get all my information (on drugs)
from reliable sources.
- Pre-selection of new scientific
information by official institutes.
Framework for community
pharmacy practice.
- Being a pharmacist, you need basic
information in all areas.
- Although I work in industry, all
these competences are needed.
- The pharmacist is a
medicines specialist.
- Response depends on the area you
are working in.
- All answers refer to daily work in a
community pharmacy.
- Answers relate to my
working environment.
- Pharmaceutical care is essential.
- Some competences are for specialists.
- Some competences are for
hospital pharmacists.
Economics/business
administration.
Cost effectiveness assessment is
a specialist role.
- It is vital to have economics and
business administration.
- “Business environment,” yes, but keep
your eye on the health aspect.
- Pharmacists follow recommendations
of NICE not cost effectiveness.
No prescription.
- Pharmacists are not allowed to
prescribe in my country.
- Pharmacists are not physicians.
Healthcare team. Pharmacists are responsible for their part ofthe job.
Subject areas.
- You need basic knowledge of
all areas.
- Pharmacognosy is no longer a
required subject.
- Radio-pharmacy would be useful.
We do not need analytical chemistry as we
are not analyzing any more.
Industrial
pharmacy/research.
- These apply to
industrial pharmacists.
- These competences are esoteric.
- Preclinical issues are not part of my
work experience.
- I have never worked in industry.
- These competences are for industry
and research.
Consultation/diagnosis.
- A pharmacist is not a doctor.
- It is not uncommon that the
pharmacist is the first person to whom
the patient explains his symptoms.
- We are not appropriately trained
for this.
- Commercial interests are involved.
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Globally, the comments leave a subjective impression of backing up the scores, but, as explained
in Section 2, no solid conclusions can be drawn.
4. Conclusions
Competences centering on values, communication skills, etc. were ranked similarly by the
two groups of pharmacists (industrial and community). In other areas, such as (1) drug research,
development and production, and (2) patient care, scores suggest that the groups appeared to be
ranking in the context of their own specific activity. These results are discussed in the light of the
existence of, or need for, an “industrial pharmacy” specialization based on a specific competence
framework. The latter is provided by the PHAR-QA framework.
The pharmacists’ perception of their profession is primarily determined within the context of their
specific activities in their line of work. The split in opinion lies between “hard sciences” and “patient
care.” The truth is that the pharmacy service that best serves the population at large involves both.
Pharmacy students seldom know in advance whether they will end up working as industrial or as
community pharmacists. Taking this into account, one could argue that a pharmacist should receive a
balanced education involving the two areas and then specialize in one of the two as his/her professional
career advances, post-registration. On the other hand, if the degree of specialization necessary is so
profound that it would be best to start it from the educational phase, the specialty-oriented program
may be the better solution. The discussion on this dilemma continues.
5. Perspectives
In light of the rankings and comments, a revised version of the competence framework will be
sent out for survey. This will be followed by the proposal of a PHAR-QA competence framework for
pharmacy practice.
Future papers will deal with results for hospital pharmacists, and academics. These papers, as
does the present paper, will deal with the implications of the results obtained, thus contributing to
the ongoing debate on the perceptions of professional identity of a pharmacist [17], in this case, with
contributions that are backed up by hard data.
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Appendix A. Ranking of Competences by Industrial and Community Pharmacists. (Seq.: Sequential Numbering (as in Figures).
Cluster Seq. Competence Industrial Pharmacists Community Pharmacists
Cluster 7. Personal competences:
learning and knowledge. 83.6 79.2
1 Ability to identify learning needs and to learn independently(including continuous professional development (CPD)). 93.3 89.8
2 Analysis: ability to apply logic to problem solving, evaluating prosand cons and following up on the solution found. 97.0 91.1
3 Synthesis: capacity to gather and critically appraise relevantknowledge and to summarise the key points. 92.4 87.9
4 Capacity to evaluate scientific data in line with current scientificand technological knowledge. 88.1 75.8
5 Ability to interpret preclinical and clinical evidence-based medicalscience and apply the knowledge to pharmaceutical practice. 71.5 75.9
6 Ability to design and conduct research usingappropriate methodology. 57.6 40.2
7 Ability to maintain current knowledge of relevant legislation andcodes of pharmacy practice. 84.6 91.7
Cluster 8. Personal competences: values. 91.7 93.7
8 Demonstrate a professional approach to tasks and human relations. 93.9 94.5
9 Demonstrate the ability to maintain confidentiality. 96.9 95.3
10 Take full personal responsibility for patient care and other aspectsof one’s practice. 86.7 94.8
11 Inspire the confidence of others in one’s actions and advice. 86.0 88.8
12 Demonstrate high ethical standards. 94.7 95.2
Cluster 9. Personal competences:
communication and organizational skills. 78.7 76.3
13 Effective communication skills (both orally and written). 89.3 94.8
14 Effective use of information technology. 86.3 86.1
15 Ability to work effectively as part of a team. 89.1 89.2
16
Ability to identify and implement legal and professional
requirements relating to employment (e.g., for pharmacy
technicians) and to safety in the workplace.
82.2 81.0
17 Ability to contribute to the learning and training of staff. 77.1 82.5
18 Ability to design and manage the development processes in theproduction of medicines. 72.8 43.2
19 Ability to identify and manage risk and quality of service issues. 78.9 79.2
20 Ability to identify the need for new services. 62.9 64.5
21 Ability to communicate in English and/or locallyrelevant languages. 85.2 74.1
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22 Ability to evaluate issues related to quality of service. 80.2 77.9
23 Ability to negotiate, understand a business environment anddevelop entrepreneurship. 61.2 64.1
Cluster 10. Personal competences:
knowledge of different areas of the
science of medicines.
63.8 66.1
24 Plant and animal biology. 23.3 39.3
25 Physics. 33.3 21.7
26 General and inorganic chemistry. 53.1 43.9
27 Organic and medicinal/pharmaceutical chemistry. 76.7 66.0
28 Analytical chemistry. 67.2 41.9
29 General and applied biochemistry (medicinal and clinical). 71.9 68.8
30 Anatomy and physiology; medical terminology. 70.3 88.7
31 Microbiology. 59.2 72.2
32 Pharmacology including pharmacokinetics. 88.4 94.7
33 Pharmacotherapy and pharmaco-epidemiology. 75.8 94.3
34 Pharmaceutical technology including analyses of medicinalproducts. 84.4 62.0
35 Toxicology. 65.1 74.0
36 Pharmacognosy. 37.5 66.5
37 Legislation and professional ethics. 86.8 89.5
Cluster 11. Personal competences:
understanding of industrial pharmacy. 70.7 59.7
38 Current knowledge of design, synthesis, isolation,characterization and biological evaluation of active substances. 57.1 41.7
39 Current knowledge of good manufacturing practice (GMP) andof good laboratory practice (GLP). 81.9 59.4
40 Current knowledge of European directives on qualified persons(QPs). 66.7 43.7
41 Current knowledge of drug registration, licensing andmarketing. 84.1 55.7
42 Current knowledge of good clinical practice (GCP). 63.5 64.5
Cluster 12. Patient care competences:
patient consultation and assessment. 52.0 77.0
43 Ability to perform and interpret medical laboratory tests. 44.4 65.5
44
Ability to perform appropriate diagnostic or physiological tests
to inform clinical decision making e.g., measurement of blood
pressure.
40.9 73.6
45
Ability to recognise when referral to another member of the
healthcare team is needed because a potential clinical problem
is identified (pharmaceutical, medical, psychological or social).
71.9 91.7
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Cluster 13. Patient care competences:
need for drug treatment. 66.0 87.0
46 Retrieval and interpretation of relevant information on thepatient’s clinical background. 63.3 84.0
47 Retrieval and interpretation of an accurate and comprehensivedrug history if and when required. 69.6 91.5
48 Identification of non-adherence and implementation ofappropriate patient intervention. 63.8 86.8
49 Ability to advise to physicians and—in some cases—prescribemedication. 66.7 87.6
Cluster 14. Patient care competences:
drug interactions. 69 93
50
Identification, understanding and prioritization of drug-drug
interactions at a molecular level (e.g., use of codeine with
paracetamol).
70.4 91.6
51
Identification, understanding, and prioritization of drug-patient
interactions, including those that preclude or require the use of
a specific drug (e.g., trastuzumab for treatment of breast cancer
in women with HER2 overexpression).
64.9 89.7
52 Identification, understanding, and prioritization of drug-diseaseinteractions (e.g., NSAIDs in heart failure). 71.7 96.6
Cluster 15. Patient care competences:
provision of drug product. 73.1 83.3
53 Familiarity with the bio-pharmaceutical, pharmacodynamic andpharmacokinetic activity of a substance in the body. 70.4 81.2
54 Supply of appropriate medicines taking into account dose, correctformulation, concentration, administration route and timing. 85.2 94.9
55 Critical evaluation of the prescription to ensure that it isclinically appropriate and legal. 77.6 94.0
56 Familiarity with the supply chain of medicines and the ability toensure timely flow of drug products to the patient. 71.1 84.6
57 Ability to manufacture medicinal products that are notcommercially available. 60.6 60.5
Cluster 16. Patient care competences:
patient education. 64.0 85.0
58 Promotion of public health in collaboration with other actors inthe healthcare system. 62.8 82.6
59 Provision of appropriate lifestyle advice on smoking, obesity,etc. 57.1 80.9
60 Provision of appropriate advice on resistance to antibiotics andsimilar public health issues. 73.0 93.1
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Cluster 17. Patient care competences:
provision of information and service. 73.0 93.0
61 Ability to use effective consultations to identify the patient’sneed for information. 68.5 90.9
62 Provision of accurate and appropriate information onprescription medicines. 80.9 94.4
63
Provision of informed support for patients in selection and use
of non-prescription medicines for minor ailments (e.g., cough
remedies...).
70.9 94.0
Cluster 18. Patient care competences:
monitoring of drug therapy. 74.0 86.0
64
Identification and prioritization of problems in the management
of medicines in a timely manner and with sufficient efficacy to
ensure patient safety.
76.9 93.0
65
Ability to monitor and report to all concerned in a timely manner,
and in accordance with current regulatory guidelines on Good
Pharmacovigilance Practices (GVPs), Adverse Drug Events and
Reactions (ADEs and ADRs).
81.1 83.4
66
Undertaking of a critical evaluation of prescribed medicines to
confirm that current clinical guidelines are appropriately
applied.
65.1 80.6
Cluster 19. Patient care competences:
evaluation of outcomes. 54.0 70.0
67 Assessment of outcomes on the monitoring of patient care andfollow-up interventions. 60.2 79.0
68 Evaluation of cost effectiveness of treatment. 47.3 61.2
Notes: Competences in bold are those showing a statistically significant difference in distribution of rankings between groups (chi-square, p < 0.05).
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